Innovative Medical (002173) announced on May 29 that it received a warning letter from the Zhejiang Regulatory Bureau of the China Securities Regulatory Commission on May 28, 2026, regarding Chen Xiaying, Chen Haijun, and Zhejiang Merchants Venture Capital Co., Ltd. (hereinafter referred to as Zhejiang Merchants Venture Capital).

During an on-site inspection, the Zhejiang Regulatory Bureau found that on March 26, 2015, Chen Xiaying, the controlling shareholder and actual controller of Innovative Medical Management Co., Ltd., and his concerted actor Chen Haijun signed a "Cooperation Framework Agreement" with Zhejiang Merchants Venture Capital, which involved significant changes in the company's equity. Subsequently, related supporting agreements were signed with designated entities of Zhejiang Merchants Venture Capital. The signing of the "Cooperation Framework Agreement" and related supporting agreements was not timely disclosed to the listed company, and the relevant information disclosure obligations were not fulfilled. In the "Report on Issuing Shares to Purchase Assets and Raising Supporting Funds and Related Transactions (Revised)" disclosed by the listed company on November 30, 2015, and in the earlier related major asset restructuring application materials, the contents of the "Cooperation Framework Agreement" and related supporting agreements were not highlighted as significant matters. The failure to fulfill the information disclosure obligations as required violated relevant regulations. According to relevant regulations, the Zhejiang Regulatory Bureau decided to issue warning letters to Chen Xiaying, Chen Haijun, and Zhejiang Merchants Venture Capital as a supervisory management measure, and these will be recorded in the integrity archives of the securities and futures market.

According to Wall Street Finance, the company is a listed company primarily engaged in providing medical services. Currently, it has four medical institutions under its umbrella: Jianhua Hospital, Kanghua Hospital, Futian Hospital, and Mingzhu Hospital. The four hospitals adhere to quality as the foundation, starting from patient needs, continuously improving medical technology and service quality, and are committed to creating medical institutions that the general public can trust for treatment. In addition, the company focuses on the development strategy of "large specialties, small comprehensives," centers on clinical services, consolidates and develops key departments and specialty disciplines, and effectively improves the overall management level of the hospitals through the construction and improvement of the internal control system